REFERENCES
- E R. History of cannabis as a medicine. The Medicinal Use of Cannabis and Cannabinoids, G W Guy. Pharmaceutical Press, Chicago 2004
- Mechoulam R, Gaoni Y. A total synthesis of Dl-Delta-1-tetrahydrocannabinol, the active constituent of hashish. J Am Chem Soc 1965; 87: 3273–3275
- Howlett A C, Barth F, Bonner T I, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54(2)161–202
- Iskedjian M, Bereza B, Gordon A, Piwko C, Einarson T R. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin 2007; 23(1)17–24
- Zajicek J P, Sanders H P, Wright D E, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 2005; 76(12)1664–1669
- Rogers W H, Wittink H M, Ashburn M A, Cynn D, Carr D B. Using the “TOPS,” an outcomes instrument for multidisciplinary outpatient pain treatment. Pain Med 2000; 1(1)55–67
- Ho M J, LaFleur J. The treatment outcomes of pain survey (TOPS): a clinical monitoring and outcomes instrument for chronic pain practice and research. J Pain Palliat Care Pharmacother 2004; 18(2)49–59
- Gershkovich P, Qadri B, Yacovan A, Amselem S, Hoffman A. Different impacts of intestinal lymphatic transport on the oral bioavailability of structurally similar synthetic lipophilic cannabinoids: dexanabinol and PRS-211,220. Eur J Pharm Sci 2007; 31(5)298–305
- Schley M, Legler A, Skopp G, Schmelz M, Konrad C, Rukwied R. Delta-9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief. Curr Med Res Opin 2006; 22(7)1269–1276